Last reviewed · How we verify
Losartan (+) amlodipine
This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.
This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance. Used for Hypertension.
At a glance
| Generic name | Losartan (+) amlodipine |
|---|---|
| Also known as | COZAAR XQ™ |
| Sponsor | Organon and Co |
| Drug class | Angiotensin II receptor blocker + calcium channel blocker combination |
| Target | AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, they provide complementary antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Peripheral edema
- Hyperkalemia
- Cough
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan (+) amlodipine CI brief — competitive landscape report
- Losartan (+) amlodipine updates RSS · CI watch RSS
- Organon and Co portfolio CI